Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.58 |
| ▸ | MME | P08473 | 3/20 | 0.53 |
| ▸ | ACE | P12821 | 2/20 | 0.53 |
| ▸ | CPA1 | P15085 | 2/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.52 |
| ▸ | REN | P00797 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 7/20 | 0.47 |
| ▸ | MMP1 | P03956 | 2/20 | 0.47 |
| ▸ | MMP3 | P08254 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31181261 | 0.91 | GNPAT (0.58) | GNPATCTRB1 | |
| SCHEMBL31181219 | 0.90 | GNPAT (0.57) | GNPAT | |
| SCHEMBL30799883 | 0.89 | MME (0.56) | GNPATMMEACECPA1ACE2 | |
| SCHEMBL11799997 | 0.89 | MME (0.56) | GNPATMMEACECPA1ACE2 | |
| SCHEMBL30799717 | 0.88 | GNPAT (0.55) | GNPATMMEACECPA1ACE2 | |
| SCHEMBL30799731 | 0.88 | MME (0.55) | GNPATMMEACECPA1ACE2 | |
| SCHEMBL12516677 | 0.88 | GNPAT (0.55) | GNPATMMEACECPA1ACE2 | |
| SCHEMBL31181231 | 0.87 | OPRM1 (0.56) | GNPATMMEACECPA1ACE2 | |
| SCHEMBL30799650 | 0.87 | OPRD1 (0.55) | GNPATOPRM1OPRD1RENMMP2 | |
| SCHEMBL30799679 | 0.87 | CTRB1 (0.56) | MMEACECTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | GNPAT 3689/4885MME 467/4885ACE 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.